Healthcare Pricing and Reimbursement in US Reviewed in New FirstWord Study Recently Published at MarketPublishers.com
02 Mar 2012 • by Natalie Aster
LONDON – Public healthcare costs are rising. Governments need to get them under control. In Europe, that means the systematic use of health technology assessments (HTA) and reference pricing. The US, on the other hand, focuses on comparative effectiveness research (CER) to identify drugs that maximise clinical efficacy, minimise clinical harm and are more in tune with individual needs.
New market report "Pricing and Reimbursement Trends in the US: Impact of Comparative Effectiveness Research and Cost-Effectiveness Analysis" worked out by FirstWord offers an insightful examination of the US model by defining comparative effectiveness research and exploring its limitations with regards to drug trials.
- wide-ranging analysis of US drug and reimbursement policies and how they differ from European models;
- review of the use of CER in the US, with particular attention to Medicaid and Medicare;
- up-to-date insight into the role of branded biologics and biosimilars in the US market;
- insight into cost-containing managed care tools;
- examination of the benefits and drawbacks of head-to-head trials and combination therapy;
- analysis of future CER proposals and their implications.
Pricing and Reimbursement Trends in the US: Impact of Comparative Effectiveness Research and Cost-Effectiveness Analysis
Published: January, 2012
Price: US$ 695,00
More new market research reports by the publisher can be found at FirstWord page.